The improved cash runway into 2028 reduces near-term dilution risk, but value inflection hinges on upcoming Phase 3 trial initiations and data readouts. Monitor enrollment progress in the pivotal IPF cough trials and any protocol finalizations with the FDA.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 18 $10.69entry
- T+1 · 8mo ago +0.09%α +0.36% · $10.70
- T+5 · 8mo ago +7.02%α +7.73% · $11.44
- T+20 · 7mo ago +36.02%α +29.97% · $14.54
- T+60 · 5mo ago +25.91%α +14.39% · $13.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics reported fourth quarter and full-year 2025 financial results, highlighted by a reduced net loss and $188.3 million in cash, providing runway into 2028. The company gained FDA alignment on its Phase 3 program for IPF-related chronic cough and plans to initiate pivotal trials in 2026, alongside Phase 2b trials in RCC and non-IPF ILD. Despite no revenue, R&D spending declined while cash position strengthened.
Key Financial Metrics
Key Facts
- Ended 2025 with $188.3 million in cash, cash equivalents, and marketable securities, up from $107.6 million in 2024.
- Net loss for Q4 2025 was $8.3 million vs. $11.4 million in Q4 2024; full-year net loss was $42.8 million vs. $47.9 million in 2024.
- R&D expenses decreased to $33.5 million in 2025 from $39.4 million in 2024 due to reduced clinical trial activity.
- Gained FDA alignment on Phase 3 trial design for IPF-related chronic cough; first pivotal trial to start in Q2 2026.
- Plans to initiate Phase 2b trials in refractory chronic cough (RCC) and non-IPF ILD in 2026.
Financial Impact
Reduced annual net loss by $5.1 million YoY; cash position increased by $80.7 million due to prior financing and interest income.
Risk Factors
- Clinical development risk: Phase 3 trials are not yet initiated; FDA may require protocol changes.
- No revenue-generating products; entirely dependent on clinical success and future funding.
- Forward-looking statements dominate; actual trial outcomes may differ from management expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257652 |
Track record
12 reports on TRVI
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Viewing Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers